SmithKline Beecham/T-Cell Sciences' sCR1
Executive Summary
IND filed for soluble complement receptor protein product sCR1 to treat adult respiratory distress syndrome (ARDS), the two companies announce Aug. 4. Developed by T-Cell Sciences, sCR1 initially will be studied in burn patients at risk of developing ARDS. SmithKline Beecham, which holds worldwide manufacturing and marketing rights to sCR1, filed the IND.